FI952930L - Pysyvien sinkki-insuliinianalogikiteiden valmistaminen - Google Patents

Pysyvien sinkki-insuliinianalogikiteiden valmistaminen Download PDF

Info

Publication number
FI952930L
FI952930L FI952930A FI952930A FI952930L FI 952930 L FI952930 L FI 952930L FI 952930 A FI952930 A FI 952930A FI 952930 A FI952930 A FI 952930A FI 952930 L FI952930 L FI 952930L
Authority
FI
Finland
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
FI952930A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952930A7 (fi
FI952930A0 (fi
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952930(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of FI952930A0 publication Critical patent/FI952930A0/fi
Publication of FI952930L publication Critical patent/FI952930L/fi
Publication of FI952930A7 publication Critical patent/FI952930A7/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
FI952930A 1994-06-16 1995-06-14 Pysyvien sinkki-insuliinianalogikiteiden valmistaminen FI952930A7 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (3)

Publication Number Publication Date
FI952930A0 FI952930A0 (fi) 1995-06-14
FI952930L true FI952930L (fi) 1995-12-17
FI952930A7 FI952930A7 (fi) 1995-12-17

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952930A FI952930A7 (fi) 1994-06-16 1995-06-14 Pysyvien sinkki-insuliinianalogikiteiden valmistaminen

Country Status (29)

Country Link
US (1) US5504188A (OSRAM)
EP (1) EP0692489B1 (OSRAM)
JP (1) JP3595607B2 (OSRAM)
KR (1) KR100369951B1 (OSRAM)
CN (1) CN1184234C (OSRAM)
AT (1) ATE233278T1 (OSRAM)
AU (1) AU697794B2 (OSRAM)
BR (1) BR9502798A (OSRAM)
CA (1) CA2151563C (OSRAM)
CO (1) CO4410205A1 (OSRAM)
CZ (1) CZ286066B6 (OSRAM)
DE (1) DE69529708T2 (OSRAM)
DK (1) DK0692489T3 (OSRAM)
ES (1) ES2188637T3 (OSRAM)
FI (1) FI952930A7 (OSRAM)
HU (1) HUT73495A (OSRAM)
IL (1) IL114152A (OSRAM)
IN (1) IN178919B (OSRAM)
MY (1) MY130551A (OSRAM)
NO (1) NO952334L (OSRAM)
NZ (1) NZ272358A (OSRAM)
PE (1) PE21896A1 (OSRAM)
PL (1) PL180968B1 (OSRAM)
RO (1) RO113529B1 (OSRAM)
RU (1) RU2156257C2 (OSRAM)
SI (1) SI0692489T1 (OSRAM)
TW (1) TW379228B (OSRAM)
YU (1) YU39595A (OSRAM)
ZA (1) ZA954942B (OSRAM)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
WO1998042367A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU1375199A (en) * 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
UA65636C2 (uk) * 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
WO2000023099A1 (en) * 1998-10-16 2000-04-27 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
BR0207422A (pt) * 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 11β−ヒドロキシステロイドデヒドロゲナーゼ1型化活性化合物
EP2394656B1 (en) 2003-11-20 2023-12-13 Novo Nordisk A/S Pharmaceutical formulations comprising the peptide liraglutide and propylene glycol
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
KR20070085227A (ko) * 2004-08-09 2007-08-27 앨리오스 바이오파마 인크. 합성 초글리코실화, 프로테아제 저항성 폴리펩티드 변이체,경구 제제 및 이를 이용한 방법
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US20090054305A1 (en) 2006-03-15 2009-02-26 Novo Nordisk A/S Mixtures of Amylin and Insulin
WO2007110364A1 (en) 2006-03-28 2007-10-04 High Point Pharmaceuticals, Llc Benzothiazoles having histamine h3 receptor activity
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2378574T3 (es) 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PT2079732E (pt) 2006-05-29 2012-02-02 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2164458A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
MX2010003979A (es) * 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
CA2744383C (en) 2008-11-21 2017-04-25 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
WO2010088286A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
CN102471368A (zh) * 2009-08-11 2012-05-23 拜康有限公司 色谱方法及其纯化的化合物
WO2012104339A1 (en) 2011-02-01 2012-08-09 Novo Nordisk A/S Purification of insulin
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6410790B2 (ja) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019125879A2 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP4126058A1 (en) 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
IL302775A (en) 2020-11-19 2023-07-01 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533298A (OSRAM) *
BE533252A (OSRAM) *
BE515508A (OSRAM) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
US5149777A (en) * 1988-07-20 1992-09-22 Novo Nordisk A/S Human insulin analogs and preparations containing them
HUT56857A (en) * 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
AU682061B2 (en) * 1993-09-17 1997-09-18 Novo Nordisk A/S Acylated insulin
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina

Also Published As

Publication number Publication date
PL180968B1 (pl) 2001-05-31
RU95110107A (ru) 1997-05-10
MY130551A (en) 2007-06-29
NO952334L (no) 1995-12-18
KR960000922A (ko) 1996-01-25
YU39595A (sh) 1997-08-22
PE21896A1 (es) 1996-06-15
SI0692489T1 (en) 2003-06-30
DE69529708D1 (de) 2003-04-03
CN1128271A (zh) 1996-08-07
BR9502798A (pt) 1996-06-04
IL114152A0 (en) 1995-10-31
EP0692489A1 (en) 1996-01-17
IL114152A (en) 1999-12-31
FI952930A7 (fi) 1995-12-17
AU2168195A (en) 1996-01-04
ZA954942B (en) 1996-12-17
RU2156257C2 (ru) 2000-09-20
EP0692489B1 (en) 2003-02-26
CN1184234C (zh) 2005-01-12
CA2151563C (en) 2007-08-07
CA2151563A1 (en) 1995-12-17
CO4410205A1 (es) 1997-01-09
DK0692489T3 (da) 2003-03-31
ATE233278T1 (de) 2003-03-15
TW379228B (en) 2000-01-11
ES2188637T3 (es) 2003-07-01
CZ286066B6 (cs) 2000-01-12
NO952334D0 (no) 1995-06-13
DE69529708T2 (de) 2003-10-16
RO113529B1 (ro) 1998-08-28
IN178919B (OSRAM) 1997-07-19
PL309099A1 (en) 1995-12-27
HU9501715D0 (en) 1995-08-28
KR100369951B1 (ko) 2003-03-28
HUT73495A (en) 1996-08-28
FI952930A0 (fi) 1995-06-14
JP3595607B2 (ja) 2004-12-02
AU697794B2 (en) 1998-10-15
NZ272358A (en) 1996-12-20
CZ154195A3 (en) 1996-02-14
US5504188A (en) 1996-04-02
JPH08169899A (ja) 1996-07-02

Similar Documents

Publication Publication Date Title
FI952930L (fi) Pysyvien sinkki-insuliinianalogikiteiden valmistaminen
FI952932A0 (fi) Monomeeriset insuliinianalogivalmisteet
DK67795A (da) Insulinanalog-formuleringer
AU646412B2 (en) Stable oral composition of zinc
FI952862A0 (fi) Spiropiperidiini ja homologit edistävät kasvuhormonin vapautumista
FI954541A7 (fi) Keratinosyyttikasvutekijän terapeuttisia käyttöjä
FI960750L (fi) Hermon kasvutekijän farmaseuttiset formulaatiot
ATE198275T1 (de) Subkutane implantate bestehend aus nomgestrolderivaten
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
ZA931935B (en) Preparation of substituted guanidines
FI943313A7 (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
IL85777A0 (en) Preparation of algae having improved biological effects
ZA89807B (en) Use of keto group-containing cyclic compounds
PL316306A1 (en) Insecticidal composition of active substances
IL88394A0 (en) Heterocyclic compounds and their use as insecticides
FI911644A7 (fi) Terapeuttinen yhdiste ja koostumus
GB9009571D0 (en) Expression of insecticidal proteins
FI910207A0 (fi) Fungisidisia vaikuttavien aineiden yhdistelmiä
ZA935647B (en) Treatment of sickle cell disease
AU7859391A (en) Crystals of factor d
DK137191D0 (da) Insulinpraeparat
DE59502325D1 (de) Arzneimittelszusammensetzung aus S-Milchsäure und dessen Verwendung
DE68925723D1 (de) Pyrazol-Verbindungen und ihre Herstellung und Verwendung